Clinical Trial Finder

Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.

Filters
Sort by
Multicentric, Double-blind, Randomised Controled Trial of Hyperbaric-oxygen Therapy (HBOT) Versus Placebo for Treating Vaso-Occlusive Crisis (VOC) in Sickle Cell Disease (SCD) After 8 Years Old

This is a randomised, controlled, double-blind, placebo trial of HBOT (intervention) superiority in the treatment of VOC in SCD, to demonstrate the effectiveness of HBOT for the decrease in pain level in the treatment of SCD-VOC.

Locations

154 France sites

77 Switzerland sites

Age

> 8 Years

Phase

Phase 3

LEARN MORE
A Multicentre Trial Evaluating the Efficacy and Safety of Oral Decitabine Tetrahydrouridine (NDec) in Patients With Sickle Cell Disease

This study examines how well a new, potential medicine called NDec works and is tolerated in people with sickle cell disease.

Locations

1658 United States sites

1059 India sites

447 United Kingdom sites

329 Canada sites

313 Italy sites

260 Turkey sites

235 Greece sites

183 France sites

179 Spain sites

89 South Africa sites

34 Lebanon sites

4 Switzerland sites

Age

> 18 Years

Phase

Phase 2

LEARN MORE
A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis

The purpose of the Phase 2 CSEG101B2201 study is to confirm and to establish appropriate dosing and to evaluate the safety in pediatric participants ages 6 months to <18 years with a history of VOC with or without HU/HC, receiving crizanlizumab for 2 years.

Locations

1673 United States sites

399 Spain sites

318 Belgium sites

242 United Kingdom sites

240 India sites

239 Germany sites

238 Brazil sites

238 Colombia sites

238 Italy sites

160 Canada sites

160 Lebanon sites

160 Turkey sites

81 Switzerland site

80 France sites

79 Oman sites

Age

6 Months - 17 Years

Phase

Phase 2

LEARN MORE